Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Author Interviews
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Transparent Process
Open Access

BACE2 distribution in major brain cell types and identification of novel substrates

Iryna Voytyuk, Stephan A Mueller, Julia Herber, An Snellinx, Dieder Moechars, View ORCID ProfileGeert van Loo, Stefan F Lichtenthaler, View ORCID ProfileBart De Strooper  Correspondence email
Iryna Voytyuk
1Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium
2Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephan A Mueller
3German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
4Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Herber
3German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
4Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
An Snellinx
1Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium
2Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dieder Moechars
5Discovery Neuroscience, Janssen Research and Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geert van Loo
6Center for Inflammation Research, VIB, Gent, Belgium
7Department of Biomedical Molecular Biology, Gent University, Gent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Geert van Loo
Stefan F Lichtenthaler
3German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
4Neuroproteomics, School of Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
8Institute for Advanced Study, Technische Universität München, Munich, Germany
9Munich Cluster for Systems Neurology, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart De Strooper
1Department of Neurosciences, Katholieke Universiteit Leuven, Leuven, Belgium
2Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium
9Munich Cluster for Systems Neurology, Munich, Germany
10Dementia Research Institute, Institute of Neurology, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bart De Strooper
  • For correspondence: Bart.DeStrooper@kuleuven.vib.be
Published 15 February 2018. DOI: 10.26508/lsa.201800026
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Supplementary Materials
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. Bace2 mRNA expression in neurons, astrocytes, and oligodendrocytes.

    Examples of Bace2 mRNA expression in neurons (A), astrocytes (B), and oligodendrocytes (C) as identified by co-localized cell type–specific markers Syp, Glast, and Mbp, respectively. Brain areas with highest neuronal (D), astrocyte (E), and oligodendrocyte (F) expression of Bace2. Neurons (G), as well as oligodendrocytes (H), expressing Bace2 also express Bace1. Purkinje cells express only Bace1 (I); similarly, dorsal hippocampus shows high Bace1 expression, but is virtually devoid of Bace2 (J). Few astrocytes throughout the brain focally express Bace1, whereas Bace2 is only expressed by astrocytes lining the lateral ventricle (K). Representative images from two adult (4 mo) and two young (P16–20) male WT mice. Syp, neuronal marker; Glast, astrocytic marker; and Mbp, oligodendrocyte marker.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Relative expression levels of known mRNA selected as points of reference.

    mRNA expression is assigned as very low (+), low (++), medium (+++), high (++++), and very high (+++++). Polr2a, Ppib, and Ubc are housekeeping brain-specific genes previously studied with RNAscope, and Syp and Glast are known cell type markers. The expression levels are also reported from Brain RNA Seq database (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html). FPKM, fragments per kilobase of transcript per million mapped reads.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. BACE2 substrates in mouse CSF.

    Volcano plot of proteomic analysis of CSF from Bace1−/− and dKO mice (n = 5). For each relatively quantified protein (representing a dot on the plot), the log2-transformed LFQ intensity ratios of dKO/Bace1−/− was plotted against the −log10-transformed t test P-values. Proteins with a t test P-value <0.05 are marked with open red circles, whereas proteins with P-value >0.05 are shown in blue. Labeled in bold black letters are the four previously identified BACE1 substrate candidates. In green are other transmembrane proteins, not previously identified as substrates of BACE1 or BACE2. No corrections for multiple hypothesis testing were applied in this discovery experiment.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. BACE2 secretome in primary glia cultures.

    (A) Volcano plot of proteomic analysis of conditioned medium from Bace1−/− cultured glia treated with BACE inhibitor CpJ or vehicle (n = 3). For each relatively quantified protein (representing a dot on the plot), the −log10-transformed t test P-value was plotted against the log2-transformed LFQ intensity ratios of CpJ/vehicle. Proteins with a t test P-value <0.05 are marked with open red circles, whereas proteins with P-value >0.05 are shown in blue. Closed red dots labeled with bold letters denote the four substrate candidates that are reduced by more than 30% in the inhibitor-treated samples. No corrections for multiple hypothesis testing were applied in this discovery experiment. (B) Uniprot subcellular locations of the identified proteins. Glycoproteins were defined according to UniProt Keywords. (C) Topology of membrane proteins according to Uniprot subcellular locations. (D) Uniprot Topology of DNER, FGFR1, PLXDC2, and VCAM1 with mapped identified peptides.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Validation of VCAM1 and DNER as BACE2 substrates in primary mixed glia cultures.

    (A) VCAM1 in medium and cell lysates of Bace1−/− glia treated with vehicle or CpJ (10 μM) for 24 h (n = 4). (B) Quantification of VCAM1 shedding into conditioned medium of Bace1−/− glia treated with vehicle or CpJ for 24 h (paired t test, P = 0.01, n = 4). (C) Quantification of VCAM1 accumulation in cell lysates of Bace1−/− glia treated with vehicle or CpJ (10 μM) for 24 h (paired t test, P = 0.08, n = 4). (D) VCAM1 shedding in WT, Bace1−/−, and Bace2−/− glia (n = 3). (E) VCAM1 in medium and cell lysates of WT glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3). (F) VCAM1 in medium and cell lysates of Bace2−/− glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3). (G) DNER in medium and cell lysates of Bace1−/− glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3). (H) Quantification of DNER shedding into conditioned medium of Bace1−/− glia treated with vehicle or CpJ for 24 h (paired t test, P = 0.03, n = 3). (I) Quantification of DNER accumulation in cell lysates of Bace1−/− glia treated with vehicle or CpJ for 24 h (paired t test, P = 0.3, n = 3). (J) DNER shedding in WT, Bace1−/−, and Bace2−/− glia (n = 3). (K) DNER in medium and cell lysates of WT glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3). (L) DNER in medium and cell lysates of Bace2−/− glia treated with vehicle or CpJ (10 μM) for 24 h (n = 3).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. Validation of FGFR1 and PLXDC2 as BACE2 substrates in COS-1 overexpression system.

    (A) FGFR1 in lysates and medium of COS-1 cells overexpressing FGFR1 alone (lane 2), FGFR1 with BACE1 (lanes 3 and 4), and FGFR1 with BACE2 (lanes 5 and 6). Lanes 4 and 6 were treated with inhibitor CpJ (10 μM). Lane 1 was mock-transfected with an empty vector. Representative for three experiments. (B) PLXDC2 in medium (top panel) and lysates (second panel from the top) of COS-1 cells overexpressing PLXDC2 alone (lane 2), PLXDC2 with BACE1 (lanes 3 and 4), and PLXDC2 with BACE2 (lanes 5 and 6). Lanes 4 and 6 were treated with inhibitor CpJ (10 μM). Lane 1 was mock-transfected with an empty vector. Control blots for BACE1, BACE2, and actin are shown for each transfection. Representative for three experiments.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. Absence of effects on VCAM1 and DNER in CSF of Bace−/− mice.

    (A) Shed VCAM1 and DNER in triplicates of CSF of 11-mo-old WT, Bace1−/−, Bace2−/−, and dKO male mice, as compared with a known BACE1 substrate—SEZ6. (B) SEZ6 is significantly reduced in Bace1−/− and dKO, but not Bace2−/− CSF compared with control WT CSF (one-way ANOVA: P = 0.006, P = 0.008, and P = 1.00, respectively; n = 3). (C) One-way ANOVA revealed no significant differences between shed DNER in Bace1−/−, Bace2−/−, and dKO CSF, as compared with WT (P = 1.00, P = 1.00, and P = 0.77, respectively; n = 3). (D) No significant differences were seen between shed VCAM1 in Bace1−/−, Bace2−/−, dKO, and WT CSF by one-way ANOVA (P = 0.76, P = 1.00, and P = 1.00, respectively; n = 3).

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. Validation of BACE2 substrate candidates in mouse brain.

    (A) DNER in the soluble TBS fraction and total cell lysates of homogenized cortex from 11-mo-old WT, Bace1−/−, Bace2−/−, and dKO male mice. Actin is used as a loading control. (B) Quantification of soluble DNER in the TBS fraction showed no significant differences between the four genotypes as analyzed by one-way ANOVA (P = 1.00 for Bace1−/− versus WT, P = 1.00 for Bace2−/− versus WT, and P = 1.00 for dKO versus WT). (C) VCAM1 in the soluble TBS fraction and total cell lysates of homogenized cortex from 11-mo-old WT, Bace1−/−, Bace2−/−, and dKO male mice. Actin is used as a loading control. (D) Quantification of soluble VCAM1 in the TBS fraction showed no significant differences between the four genotypes as analyzed by one-way ANOVA (P = 0.31 for Bace1−/− versus WT, P = 0.59 for Bace2−/− versus WT, and P = 1.00 for dKO versus WT). (E, F) No significant differences were observed in full-length levels of DNER and VCAM1 in total cell lysates (one-way ANOVA of FL DNER: P = 0.19 for Bace1−/− versus WT, P = 0.25 for Bace2−/− versus WT, and P = 0.25 for dKO versus WT; one-way ANOVA of FL VCAM1: P = 0.16 for Bace1−/− versus WT, P = 1.00 for Bace2−/− versus WT, and P = 1.00 for dKO versus WT). (G) VCAM1 in the soluble TBS fraction and total cell lysates of homogenized subdissected ventral hippocampi from 4-mo-old WT, Bace2−/−, and dKO male mice. Actin is used as a loading control. (H) VCAM1 in the soluble TBS fraction and total cell lysates of homogenized subdissected subventricular zone from P16 WT, Bace1−/−, Bace2−/−, and dKO male mice. Actin is used as a loading control. VCAM1 (I) and DNER (J) in the soluble TBS fraction and membrane fractions of homogenized brain hemispheres from 4-mo-old Bace1−/− male mice treated with CpJ or vehicle. PSEN1 membrane protein was used as a loading control.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Validation of substrate under pro-inflammatory challenge in vitro and in vivo.

    (A) VCAM1 in medium and lysates of primary mixed glia culture treated with murine recombinant TNF (10 ng/ml) or IL-1β (10 ng/ml) for 8 h and 24 h (n = 3). Control blots for BACE1, BACE2, and actin are shown. (B) VCAM1 in medium and lysates of primary mixed glia cells treated with murine recombinant TNF (10 ng/ml) for 24 h, or treated with vehicle or CpJ inhibitor (10 μM) (n = 3). Control blots for GFAP and actin are shown. (C) VCAM1 in triplicates of CSF, TBS fraction, and total cell lysates of cortices from 11-mo-old WT male controls injected with PBS or treated with 250 μg/kg TNF. Actin is used as a loading control. (D) VCAM1 shedding into CSF is up-regulated upon TNF treatment (unpaired t test, P = 0.04; n = 3), whereas no changes are observed in full-length VCAM1 or soluble VCAM1 in TBS fraction shown in (C). (E) VCAM1 in triplicates of CSF of 11-mo-old WT or Bace2−/− mice treated with saline or 250 μg/kg TNF (top panel) and VCAM1 in triplicates of CSF of 11-mo-old Bace1−/− or Bace2−/− mice treated with saline or 250 μg/kg TNF (bottom panel). (F) Two-way ANOVA reveal significant differences in shed VCAM1 between treated and untreated WT and Bace1−/− mice (P = 0.0004 and P = 0.005, respectively; n = 3), but no significant differences in shed VCAM1 between treated and untreated Bace−/− mice (P = 0.69).

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. DNER under pro-inflammatory challenge in primary glia culture.

    DNER in medium and lysates of primary mixed glia culture treated with murine recombinant TNF (10 ng/ml) or IL-1β (10 ng/ml) for 8 h and 24 h (n = 3). Control blots for BACE2 and actin are shown.

  • Figure S5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S5. Flow chart diagrams of mice and cultures used in all primary glia experiments.

    (A) Glia cultures prepared from Bace1−/− P3 pups for the proteomics experiment depicted in Fig 2. (B) Glia cultures prepared from mice of different genotypes for the validation experiments depicted in Fig 3D and J. (C) Glia cultures prepared from mice of different genotypes for the validation experiments with BACE inhibition depicted in the remaining panels of Fig 3.

Tables

  • Figures
  • Supplementary Materials
    • View popup
    Table 1.

    Summary of BACE2 and BACE1 expression in the mouse brain.

    Brain areaBACE2 expressionBACE2 expressing cell typesBACE1 expressionBACE1 expressing cell types
    Hippocampus (dorsal)−Not found+++Neurons
    Hippocampus (ventral CA3 and subiculum)++Neurons+++Neurons
    Cortex (highest in motor and somatosensory layers 4 and 5)+Neurons++Neurons, occasional astrocytes
    Thalamus+Neurons+++Neurons, occasional astrocytes
    Cerebellum+Oligodendrocytes++Neurons, oligodendrocytes
    Striatum+Oligodendrocytes++Oligodendrocytes
    Fiber tracts+, ++ at P16Oligodendrocytes++, +++ at P16Oligodendrocytes, astrocytes
    Lateral ventricle lining+Astrocytes−Not found

Supplementary Materials

  • Figures
  • Tables
  • Table S1 Changes in protein levels in murine CSF of dKO versus Bace1−/− mice.

  • Table S2 Changes in protein levels in the secretome of glial cells as a result of BACE inhibitor treatment.

PreviousNext
Back to top
Download PDF
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
BACE2 distribution in major brain cell types and identification of novel substrates
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BACE2 brain expression and substrates
Iryna Voytyuk, Stephan A Mueller, Julia Herber, An Snellinx, Dieder Moechars, Geert van Loo, Stefan F Lichtenthaler, Bart De Strooper
Life Science Alliance Feb 2018, 1 (1) e201800026; DOI: 10.26508/lsa.201800026

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BACE2 brain expression and substrates
Iryna Voytyuk, Stephan A Mueller, Julia Herber, An Snellinx, Dieder Moechars, Geert van Loo, Stefan F Lichtenthaler, Bart De Strooper
Life Science Alliance Feb 2018, 1 (1) e201800026; DOI: 10.26508/lsa.201800026
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 1, No. 1
January 2018
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Supplementary Information
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Neuroscience

Related Articles

  • No related articles found.

Cited By...

  • Epigenetic profiling of Italian patients identified methylation sites associated with hereditary Transthyretin amyloidosis
  • Gga3 deletion and a GGA3 rare variant associated with late onset Alzheimers disease trigger BACE1 accumulation in axonal swellings
  • Quantitative secretome analysis establishes the cell type-resolved mouse brain secretome
  • AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimers disease mouse model
  • A promising, novel, and unique BACE1 inhibitor emerges in the quest to prevent Alzheimer's disease
  • Google Scholar

More in this TOC Section

  • TRIM25 targets p300 for degradation
  • Role of Tim50 in TOM–TIM23 coordination
  • SARS-CoV-2 subgenomic RNAs
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.